Valuation: PTC Therapeutics, Inc.

Market Cap 5.45B 4.76B 4.47B 4.08B 7.66B 521B 7.66B 53.55B 20.66B 266B 20.45B 20B 858B P/E 2026 *
42.4x
P/E 2027 * 23.1x
Enterprise Value 3.58B 3.12B 2.93B 2.68B 5.03B 342B 5.03B 35.15B 13.56B 175B 13.43B 13.13B 563B EV / Sales 2026 *
2.84x
EV / Sales 2027 * 2.4x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week-0.78%
Current month-5.15%
1 month-5.53%
3 months-16.49%
6 months+1.01%
Current year-13.16%
1 week 64.99
Extreme 64.99
68.84
1 month 64.99
Extreme 64.99
73.52
Current year 61.43
Extreme 61.43
90.87
1 year 57.74
Extreme 57.74
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26
Section Six Partners
SellCompany -10,000 0.0120%
9/16/26 Other

Chairman

0 0%
9/10/26
Section Six Partners
SellCompany -10,000 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-0.78%+9.06%+165.75% 5.45B
+0.45%+2.80%+55.61%+112.70% 1,038B
-0.10%+1.08%+52.78%+66.52% 649B
+0.28%+1.31%+19.21%+72.85% 467B
-0.19%+0.75%+37.34%+45.03% 355B
+0.28%+2.23%+19.12%+25.62% 269B
+0.89%+4.26%+12.10%+16.41% 260B
+4.34%+7.53%+43.74%+52.27% 213B
-0.46%-7.70%-33.40%-59.71% 176B
+1.40%+4.28%+33.82%+102.83% 187B
Average +0.62%+0.76%+24.94%+60.03% 362.06B
Weighted average by Cap. +0.50%+1.46%+36.54%+66.87%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.03B 943M 1.77B 120B 1.77B 12.37B 4.77B 61.4B 4.72B 4.62B 198B 1.38B 1.2B 1.13B 1.03B 1.94B 132B 1.94B 13.54B 5.22B 67.22B 5.17B 5.06B 217B
Net income 145M 127M 119M 109M 204M 13.9B 204M 1.43B 552M 7.1B 546M 534M 22.89B 231M 202M 190M 173M 325M 22.12B 325M 2.28B 878M 11.3B 869M 850M 36.44B
Net Debt -1.87B -1.63B -1.54B -1.4B -2.63B -179B -2.63B -18.4B -7.1B -91.35B -7.03B -6.87B -295B -2.15B -1.87B -1.76B -1.61B -3.02B -205B -3.02B -21.09B -8.14B -105B -8.06B -7.88B -338B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-09-22 US$65.96 +1.07% 1,307,186
26-09-21 US$65.26 -0.17% 1,086,197
26-09-18 US$65.37 -3.87% 3,864,989
26-09-17 US$68.00 +0.61% 1,115,270
26-09-16 US$67.59 +2.96% 1,397,906
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
65.96USD
Average target price
101.79USD
Spread / Average Target
+54.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!